Ingredion Board Grants CEO James Zallie an Exception to Mandatory Retirement Policy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
- Governance Policy Waiver: Ingredion's Board of Directors has waived the company's governance policy that mandates CEO James Zallie to retire at age 65.
- Extended Tenure: Zallie has agreed to continue in his role beyond April 2026, when he will reach the age of 65.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like INGR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on INGR
Wall Street analysts forecast INGR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INGR is 125.50 USD with a low forecast of 119.00 USD and a high forecast of 136.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 116.450
Low
119.00
Averages
125.50
High
136.00
Current: 116.450
Low
119.00
Averages
125.50
High
136.00
About INGR
Ingredion Incorporated is a global ingredient solutions provider serving customers in nearly 120 countries. The Company turns grains, fruits, vegetables and other plant-based materials into value-added ingredient solutions for the food, beverage, animal nutrition, brewing and industrial markets. Its segments include Texture & Healthful Solutions (T&HS), Food & Industrial Ingredients - Latin America (F&II - LATAM) and Food & Industrial Ingredients - U.S./Canada (F&II - U.S./Canada). Its product lines include starches and sweeteners, animal feed products and edible corn oil. Its starch-based products include both food-grade and industrial starches, as well as biomaterials and non-GMO (genetically modified organism) products. Its sweetener products include glucose syrups, high maltose syrups, high fructose corn syrup, caramel color, dextrose, polyols, maltodextrins, glucose and syrup solids, high-intensity sweeteners, and various non-GMO products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Ingredion CFO James Gray Announces Retirement Effective March 31
- Executive Change: Ingredion announced the retirement of Executive Vice President and CFO James Gray effective March 31, and while a successor has yet to be named, this move may impact investor confidence in the company's financial stability.
- Market Reaction: Following the announcement of Gray's retirement, Ingredion's stock performance is under scrutiny, particularly against the backdrop of macroeconomic uncertainty and health-focused food trends, intensifying investor expectations for future financial leadership.
- Financial Performance: Ingredion's recent Q3 2025 earnings report indicates that despite challenges, the company's market positioning aligns with health food trends, potentially providing a solid strategic direction for the incoming CFO.
- Rating Downgrade: After the Q3 results were released, Barclays downgraded Ingredion's rating, reflecting a cautious market sentiment regarding the company's future performance, especially in light of the executive transition.
Continue Reading
Lyric Appoints Halsey Wise as CEO to Drive Growth in Payment Integrity AI
- Leadership Change: Lyric announces the immediate appointment of Halsey Wise as CEO, succeeding Raj Ronanki, who transitions to an advisory role, reflecting a commitment to leadership continuity and strategic direction.
- Industry Experience: Wise brings over 30 years of experience in leading healthcare and software companies, having served as CEO of Intergraph and MedAssets, and is expected to leverage his extensive industry knowledge to drive innovation and market expansion at Lyric.
- Platform Advantage: Lyric's AI-driven platform, Lyric42, is built on 35 years of clinical expertise and integrates real-time data across 190 million lives, aiming to reduce wasted healthcare spending and ensure fast, accurate payments, thereby enhancing client transparency and satisfaction.
- Market Recognition: Lyric has been recognized as the 2025 Best in KLAS for Pre-payment Accuracy and Integrity, underscoring its leadership position in the industry and commitment to delivering value to clients, which is expected to further strengthen its competitive edge.
Continue Reading